NEW YORK, Nov. 11 (GenomeWeb News) - Lynx Therapeutics said today that it has signed a multi-year, multi-million dollar services agreement with DuPont that extends a five-year agreement the companies initiated in 1998.

Under the extended arrangement, DuPont and its subsidiary, Pioneer Hi-Bred International, will continue using Lynx's Massively Parallel Signature Sequencing (MPSS) technology for the discovery and development of new agricultural traits and products.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.